Tonix Pharmaceuticals Holding Corp.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Seth Lederman
- Full Time Employees
- 142
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 200 Connell Drive Berkeley Heights NJ United States of America 07928
- IPO Date
- May 10, 2012
- CIK
- 0001430306
- Website
- tonixpharma.com
- Similar Companies
- Business
- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) is a clinical-stage biopharmaceutical company focused on developing novel therapies for central nervous system disorders, immunology, and infectious diseases. The company offers a pipeline of product candidates including TNX-102 SL, a non-opioid sublingual tablet for fibromyalgia and acute stress reaction post-traumatic stress disorder; TNX-1300, an IV formulation of cocaine for rapid-onset cocaine intoxication; TNX-1500, a monoclonal antibody targeting CD40 ligand for organ transplant rejection and autoimmune conditions; TNX-2900, a nasal spray oxytocin antagonist for Prader-Willi syndrome; and TNX-801, a live virus vaccine for smallpox and mpox; along with TNX-1800, a live virus vaccine for SARS-CoV-2. These products target unmet medical needs in pain management, neurology, vaccinology, and biologics, serving patients through clinical development and potential commercialization. Founded in 2007 and headquartered in Chatham, New Jersey, Tonix Pharmaceuticals operates primarily in the United States with clinical trials conducted globally. In recent developments, the company reported positive Phase 3 data for TNX-102 SL in fibromyalgia during 2024, advancing toward an NDA filing expected in early 2025; expanded its infectious disease portfolio through preclinical progress on TNX-801 and TNX-1800 amid mpox outbreaks; and strengthened its balance sheet via a public offering in late 2024, supporting ongoing CNS and immunology programs. Additionally, Tonix entered a strategic collaboration with Makana Therapeutics in 2024 to co-develop TNX-1500 for transplant indications, marking a key alliance in biologics.
Tonix Pharmaceuticals Announces Publication in the Peer-Reviewed Journal of Virology Assessing Virulence of the 2022 Outbreak Strain of Mpox in New Animal Models
Tonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA®
Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD)
This Tonix Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Tonix Pharmaceuticals to Attend BTIG Infectious Disease Day 2026
Tonix Shares Jump After Landing Second Commercial Payer Agreement For TONMYA
Tonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA®, Expanding Total Commercial Coverage to ~52 Million U.S. Lives
Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis of Opioid Use in Patients with Fibromyalgia at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
Tonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of Clinical Immunology
Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at The Professional Society for Health Economics and Outcomes Research (ISPOR) 2026 Annual Meeting
Tonix Pharmaceuticals to Present Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at ISPOR 2026
Tonix Pharmaceuticals to Participate in Two Investor Conferences in May
Tonix Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Highlights
Tonix Pharmaceuticals Secures Commercial Payer Coverage for TONMYA®, Providing Access for ~35 Million U.S. Patients
Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Plans for an Adaptive Phase 2 Field Study of TNX-4800 (anti-Borrelia OspA monoclonal antibody) for the Prevention of Lyme Disease at the 4th Annual Ticks and Tickborne Diseases Symposium at Johns Hopkins University
Tonix Pharmaceuticals Presents Updates on Preclinical Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2026
Tonix Pharmaceuticals Announces Publication of Steady-State Pharmacokinetics of TONMYA® After 20 Days of Daily Dosing in the Peer-Reviewed Journal, Clinical Pharmacology in Drug Development
Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Outlines Planned Adaptive Phase 2 Field Study of TNX-4800 for the Prevention of Lyme Disease, at the World Vaccine Congress Washington 2026
Tonix Pharmaceuticals Stock Hits New 52-Week Low: What's Driving The Action?
Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and Craniofacial Pain